Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
Merck (MRK) stock surged 73% in the past year, outpacing the S&P 500, driven by successful clinical trials and FDA approvals. The company's pipeline, including LIPFENDRA and an mRNA cancer vaccine, addresses concerns about KEYTRUDA's patent expiration. Merck's forward P/E of 16x is lower than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY), suggesting potential undervaluation.
How this was made
The 30-second read
Why it matters
Regulatory approval and trial data provide fresh, material information that could shift valuation multiples and attract new capital.
Market read
Merck's FDA approval and trial results constitute a primary catalyst for the stock and may influence broader pharma sentiment.
What to watch
Potential pricing pressure and reimbursement challenges for the new oral therapy could temper upside.
Background
The article evaluates Merck's recent stock performance, attributing it to pipeline successes and addressing concerns over KEYTRUDA patent expiry.
Ticker impact
FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, and positive mRNA cancer vaccine trial data were disclosed, driving a recent surge in Merck stock.
Potential near‑term price appreciation as investors reprice the new product pipeline.
FDA approval is a material catalyst for a large‑cap pharma; combined with strong trial data it reduces risk around KEYTRUDA loss and adds $70B commercial potential.
Market effects
Strengthens the pharma sector outlook, especially for companies with oral PCSK9 candidates and mRNA oncology platforms.
U.S. biotech and pharma equities may see broader buying pressure.
Highlights the growing importance of oral biologics and mRNA therapeutics worldwide.
Counterpoint
Skeptics may argue that oral PCSK9 uptake could be slower than injectables, limiting LIPFENDRA's market share.
Key entities
- companyMerck & Co.
Large‑cap pharmaceutical company (ticker MRK).
- companyModerna
Partner in the mRNA cancer vaccine trial.
